{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"13.7","value":"8.4"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"13.7","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"A patient is a responder if the patient has a confirmed best tumor response on-study of CR (Complete response) or PR (Partial response), as determined by the central radiological reviewer per mRECIST criteria. ORR in each treatment arm was defined as the number of responders divided by the number of randomized patients. A responder was a patient who had a confirmed best tumor response on-study of CR or PR, as determined by the central radiological reviewer per mRECIST criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy analysis (ORR) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"up to approx. 30 months (data cut-off: 31-May-2017) - Time from randomization until death from any cause.","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}